FMP
NASDAQ
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
0.135 USD
0.002 (1.48%)
Valuation Date:
Apr 19, 2024 11:51 AM
Share Price on Valuation Date
$0.14
Stock Beta
-0.26
Shares Outstanding
44260700